Artiva Biotherapeutics (ARTV) announced it will discontinue development of its AlloNK (AB-101) cell therapy program and evaluate strategic alternatives, including a potential merger, business combination, asset sale or liquidation.
The company said updated longer-term clinical follow-up did not meet its required threshold for durability of response. Artiva also reported two Grade 5 events in its clinical studies and said it will reduce its workforce by approximately 94%.
- AlloNK development will end, with no additional patients to be dosed in ongoing studies and the planned Phase 3 pivotal trial not to be initiated.
- One fatal leukoencephalopathy event was assessed as likely related to fludarabine-associated neurotoxicity; a second sudden death was assessed as unrelated to study treatment.
- The FDA asked Artiva to pause enrollment and dosing in the Phase 2a study after notification of the first event.
- Artiva reported preliminary, unaudited cash, cash equivalents and investments of approximately $319.1 million as of September 30, 2026.
- Leerink Partners has been engaged as financial advisor for the strategic alternatives review.
$ARTV Insider Trading Activity
$ARTV insiders have traded $ARTV stock on the open market 38 times in the past 6 months. Of those trades, 21 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ARTV stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 19 purchases buying 8,636,021 shares for an estimated $92,620,145 and 0 sales.
- CORP. GC has made 2 purchases buying 1,432,291 shares for an estimated $16,499,992 and 0 sales.
- FRED ASLAN (Chief Executive Officer) has made 0 purchases and 5 sales selling 197,592 shares for an estimated $1,781,098.
- CHRISTOPHER HORAN (Chief Tech Operations Officer) has made 0 purchases and 3 sales selling 27,708 shares for an estimated $249,407.
- JENNIFER BUSH (COO, CLO, Compliance Officer) has made 0 purchases and 3 sales selling 25,551 shares for an estimated $230,011.
- SUBHASHIS BANERJEE (Chief Medical Officer) has made 0 purchases and 5 sales selling 17,887 shares for an estimated $187,055.
- HEATHER RAYMON (SVP, Research and Development) sold 3,095 shares for an estimated $27,879
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ARTV Hedge Fund Activity
We have seen 62 institutional investors add shares of $ARTV stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 8,102,340 shares (+82.2%) to their portfolio in Q2 2026, for an estimated $78,592,698
- VIKING GLOBAL INVESTORS LP added 2,604,166 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,260,410
- CALIGAN PARTNERS LP added 1,736,111 shares (+inf%) to their portfolio in Q2 2026, for an estimated $16,840,276
- FRANKLIN RESOURCES INC added 1,476,896 shares (+283.8%) to their portfolio in Q2 2026, for an estimated $14,325,891
- SAMSARA BIOCAPITAL, LLC added 954,861 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,262,151
- BLUE OWL CAPITAL HOLDINGS LP added 874,542 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,483,057
- PROPEL BIO MANAGEMENT, LLC added 550,067 shares (+375.8%) to their portfolio in Q2 2026, for an estimated $5,335,649
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
